Skip to main content
Premium Trial:

Request an Annual Quote

Tute Genomics, ABL Sign Software Marketing Agreement


NEW YORK (GenomeWeb) – Advanced Biological Laboratories has signed a software marketing agreement with Tute Genomics which lets the former sell access to Tute's platform in Europe, Africa, and parts of Asia.

Salt Lake City, Utah-based Tute launched its cloud-based interpretation engine last November. The s system, which is used for annotating and prioritizing genetic variants, is based on Annotate Variation, a well known open source program that was developed by Kai Wang, an assistant professor of psychiatry and preventative medicine at the University of Southern California and the company's president.

Reid Robison, Tute's CEO, said in a statement that the partnership with ABL and the broader distribution of his firm's platform should result in "greater sales growth going forward."

Also this week, ABL launched OncoChek, a new platform for managing and analyzing genomic data in the oncology space. According to the company, the newest member of its portfolio is derived from DeepChek, its existing software for next-generation sequence data analysis.

Furthermore, OncoChek pairs well with Tute's interpretation platform, according to Chalom Sayada, ABL's CEO.

"With the continuous pipeline of new features appearing in the Tute Genomics platform including a broad range of updated annotation content, and the capability to rapidly analyse whole genomes or whole exomes, there is a natural fit with our own OncoChek platform," he said. Combining the capabilities from both products, "should ease the work of laboratories and researchers by providing them with validated and professional tools that should bring new results compared with currently available products."

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.